| Disease | A TOTAL OF 18 RANDOMIZED CONTROLLED TRIALS INVOLVING 2939 MEN MET INCLUSION CRITERIA AND WERE ANALYZED. MANY STUDIES DID NOT REPORT RESULTS IN A METHOD THAT PERMITTED META-ANALYSIS. TREATMENT ALLOCATION CONCEALMENT WAS ADEQUATE IN 9 STUDIES;
16 WERE DOUBLE-BLINDED. THE MEAN STUDY DURATION WAS 9 WEEKS (RANGE, 4-18 WEEKS). AS COMAPRED WTIH MEN RECEIVING PLACEBO, MEN TREATED WITH S REPENS HAD DECREASED URINARY TRACT SYMPTOM SCORES NOCTURIA AND IMPROVEMENT IN SELF-RATING OF URINARY
TRACT SYMPTOMS; RISK RATIO FOR IMPROVEMENT AND PEAK URINE FLOW. COMPARED WITH MEN RECEIVING FINASTERIDE, MEN TREATED WITH S REPENS HAD SIMILAR IMPROVEMENTS IN URINARY TRACT SYMPTOM SCORES (WMD,0.37 INTERNATION PROSTATE SYMPTOM SCORE POINTS [
SCALE RANGE, 0-35] 995% CI, -0.45 TO 1.19] [N-1.66 TO 0.81] [N=S SGUEIES]). ADVERSE EFFECTS DUE TO S REPENS WERE MILD AND INFREQUENT; ERECTILE DYSFUNCTION WAS MORE FREQUENT WITH FINASTERIDE (4.9%) THAN WITH 2 REPENS (1.1%; P<.001). WITHDRAWAL
RATES IN MEN ASSIGNED TO PLACEBO, S REPENS; OR FINASTERIDE ERE 7%, 9%, AND 11%, RESPECTIVELY. COMAPRED WITH FINASTERIDE, S REPENS PRODUCES SIMILAR IMPROVEMENT IN URINARY TRACT SYMPTOMS AND URINARY FLOW AND WAS ASSOCIATED WITH FEWER ADVERSE
TREATMENT EVENTS. |